View more in
Cancer

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

onclive.com
 2021-06-08

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma. The BCMA-targeting humanized bispecific monoclonal antibody elranatamab (PF-06863135) elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma, according to data...

www.onclive.com

Comments / 0

Comments / 0